Product Description
Mechanisms of Action: Vitamin B5 Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Brazil | Bulgaria | Chile | Colombia | Croatia | Czech | Dominican Republic | Ecuador | Egypt | Estonia | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | New Zealand | Norway | Pakistan | Philippines | Russia | Serbia | Slovenia | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Injuries/wounds Unspecified|Diabetic Foot|Nasal Obstruction|Common Cold
Phase 2: Diabetic Foot
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| H-23015740 | N/A |
Completed |
Keratosis, Actinic |
2024-02-29 |
|
| CO2 | P3 |
Completed |
Injuries/wounds Unspecified |
2018-01-22 |
|
| NCT02615561 | N/A |
Completed |
Dermatitis, Atopic |
2016-09-07 |
|
| PEDFUT | P3 |
Completed |
Diabetic Foot |
2014-08-01 |